Skip to Content

Roche Holding AG - Stock Quote ROG

Rating as of

Morningstar's Roche Holding AG Stock Analysis

Valuation
Currency in CHF
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Roche's Tiragolumab Fails in Higher-Stakes Trial; Lowering Our FVE, but Shares Remain Undervalued

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We're lowering our Roche fair value estimates from $58/CHF 443 to $55/CHF 433 following the failure of the firm's phase 3 Skyscraper-01 trial, which tested a combination of approved oncology drug Tecentriq with TIGIT-targeting drug candidate tiragolumab in first-line treatment of PDL1-high non-small-cell lung cancer. In March, the first phase 3 readout for a Tecentriq/tiragolumab combination also failed, but this trial tested the combination with chemotherapy in small-cell lung cancer, a smaller niche that is considered more difficult to treat. While Roche did see a numerical improvement in progression-free survival and overall survival at this first look at data from Skyscraper-01, the results did not reach statistical significance, and Roche plans to follow the trial until the next interim readout. However, we're disappointed at the initial result in tiragolumab's potentially largest indication, and we're lowering our Tecentriq combination sales in lung cancer as well as our probability of approval for tiragolumab. Overall, we've lowered our 2026 Tecentriq sales forecast to CHF 8.8 billion from CHF 9.6 billion and reduced our tiragolumab sales forecast that year from CHF 1 billion (50% probability of approval) to CHF 400 million (20% probability of approval). Overall, we think Roche has a solid portfolio extending beyond oncology (including steady growth drivers like multiple sclerosis drug Ocrevus, hemophilia drug Hemlibra, Spinal muscular atrophy drug Evrysdi) that will help the firm maintain top-line growth and margin expansion, once the firm gets past difficult COVID-19 diagnostic comparables over the next year. Roche's innovation in pharma and diagnostics support a stable, wide moat, and shares look undervalued.

Read Full Analysis

Roche Holding AG's Company Profile

Business Description

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Contact
Grenzacherstrasse 124
Basel, 4070, Switzerland
T +41 616881111
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 101,465

Roche Holding AG's Related Articles & News